Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
Annals of Oncology, 11/06/09

Ennishi D et al. – A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings raised significant concerns about statin use during rituximab treatment, their clinical significance is unclear. The results of this study indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP.

Methods

Retrospective study investigating effects of statins on prognosis of diffuse large B-cell lymphoma (DLBCL) treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP)
Newly diagnosed DLBCL patients analyzed (n = 256), including 35 patients taking statins

Results

3-year PFS rates 84% and 73% , while the overall survival rates were 89% and 78% for those patients treated with and without statins, respectively
After adjusting for International Prognostic Index and serum cholesterol level, statin use is not associated with prognosis

<< Previous
Phase II study of oxaliplatin plus S-1 as first-line treatment...

Next >>
Casopitant improves the quality of life in patients receiving...